Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol)

US7625996B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Stephan Fischer · Weilheim, DE
• Friederike Hesse · Munich, DE
• Hendrik Knoetgen · Penzberg, DE
• Kurt Lang · Penzberg, DE
• Friedrich Metzger · Glückstadt, DE
• Joerg Thomas Regula · Munich, DE
• Christian Schantz · Penzberg, DE
• Andreas Schaubmar · Penzberg, DE
• Hans-Joachim Schoenfeld · Glückstadt, DE

Key dates

• Filing date: Aug 29, 2007
• Grant date: Dec 1, 2009
• Expiry date: Sep 20, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/50
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a fusion protein comprising IGF-I or an IGF-I variant N-terminally linked to the C-terminus of a propeptide. The invention relates also to a method involving the use of the aforementioned fusion protein in the production of a lysine-PEGylated IGF-I or IGF-I variant. The method comprises the steps of cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding the fusion protein and causing the cell to express the fusion protein, recovering and PEGylating said fusion protein, cleaving said PEGylated fusion protein with IgA protease, and recovering lysine-PEGylated IGF-I or IGF-I variant. The invention relates also to a lysine-PEGylated IGF-I or IGF-I variant produced using the above method. In addition, the invention relates to a method for treating a neurodegenerative disorders like Alzheimer's Disease using the lysine-PEGylated IGF-I or IGF-I variant and a composition comprising the lysine-PEGylated IGF-I or IGF-I variant.